HopeStage
Back to all studies
CompletedNCT00140192

Creatine Treatment in Psychiatric Disorders

Medication studyAges 18–60IsraelSchizophrenia
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Listed locations
BeershevaSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2004
Recruitment status
Completed
Enrollment listed in the registry
12
Sponsor
Beersheva Mental Health Center
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Israel
Age range
From 18 Years to 60 Years
Official registry ID
NCT00140192
Official title
Show the full official title

Creatine as a New Treatment for Schizophrenia:A Double-Blind Trial

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Beersheva

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Beersheva Mental Health Center, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including creatine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies